Three familial cases of drug-resistant Mycoplasma pneumoniae infection

Kamizono, Shintaro; Ohya, Hitomi; Higuchi, Sadanobu; Okazaki, Norio; Narita, Mitsuo

doi:10.1007/s00431-009-1100-3

Cited by 8 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The positivity rate of NPA specimens in the same period from November 2007 to March 2009 in all pneumonia children in our hospital was 16.9% (1,246 in 7,381 cases, data not published). The immunopathogenesis of M. pneumoniae pneumonia is considered to be age-dependent [10]. In our study, children with MPP were older than non-MPP, which is also in agreement of other studies [3,6,11,19,23].…”

Section: Discussionsupporting

confidence: 94%

Detection of Mycoplasma pneumoniae in different respiratory specimens

Chen

et al. 2010

Eur J Pediatr

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 94%

Detection of Mycoplasma pneumoniae in different respiratory specimens

Chen

et al. 2010

Eur J Pediatr

View full text Add to dashboard Cite

show abstract

“…Second, a previous study showed a gender difference in treatment outcomes for pneumonia ( 23 ). Meanwhile, the immunopathogenesis of MPP is regarded as age-dependent ( 24 ). Age may be the sole predisposing factor of MPP ( 25 ).…”

Section: Methodsmentioning

confidence: 99%

Effects of bronchoalveolar lavage on Mycoplasma Pneumoniae pneumonia: A propensity score matched-cohort study

Zhang

Wang

et al. 2023

Front. Pediatr.

View full text Add to dashboard Cite

BackgroundThe purpose of this study was to evaluate the efficacy and safety of BAL in treating MPP.MethodsFrom January 2013 to January 2019, 1,689 pediatric patients with MPP were analyzed retrospectively. Patients were subdivided into BAL group and non-BAL group according to whether they received BAL treatment within seven days after admission. The propensity score matching method matched patients' baseline characteristics (1:1). The primary outcomes were hospital stays and the cure rate. Secondary outcomes included mortality, co-infection, repeat hospitalization within 30 days, and total cost of treatment.ResultsAfter matching, 524 patients (BAL: 262; control: 262) were recorded. The BAL group had significantly shorter hospital stays (OR: 0.5, 95% CI: 0.4–0.7). Meanwhile, BAL did not significantly modify the cost, co-infection rate, and mortality. In subgroup analyses, the group with BAL intervention within three days had a significantly shorter hospital stay (OR: 0.4, 95% CI: 0.3–0.5) compared with the group with BAL intervention three days after admission.ConclusionsEarly BAL intervention is a better treatment than conventional drug therapy alone, and no significant complications were seen in this study. BAL intervention has an excellent clinical benefit. The earlier the intervention, the better the effect.

show abstract

“…[1,2] In recent years the incidence of M. pneumoniae pneumonia (MPP) has risen, and reports on macrolide-resistant M. pneumoniae have been increasing. [3,4] Refractory or critical MPP cases are also seen increasingly, with a great harm to children, especially those with weak immune function. climate effects.…”

Section: Introductionmentioning

confidence: 98%